Triple regimens with protease inhibitors may be superior to regimens based on non-nucleoside reverse transcriptase inhibitors and to two nucleoside reverse transcriptase inhibitor regimens in adults with advanced HIV infection. In a systematic review and indirect meta-analysis, Yazdanpanah and colleagues (p 249) analysed data on 6785 patients included in 14 trials, comparing triple and dual therapy for HIV infection. They found that, in patients with advanced disease who had been exposed to nucleoside reverse transcriptase inhibitors, protease inhibitor based triple regimens are superior to other treatment for preventing progression to AIDS or death.
Figure 1.
Credit: AMY SANCETTA/AP